Results from a phase I/II trial investigating SHR-A1811 in HER2-mutated advanced-staged and treatment-refractory NSCLC patients have shown an ORR of 38.1% and an mPFS of 9.5 months (Figure 1). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.